Novel pyrimidine carboxamides target upstream NF-kB signaling to treat chronic inflammation while avoiding COX-2 related side effects.
Modified atypical antipsychotic compounds exhibit high affinity for dopamine D2 and serotonin 5-HT2A receptors, reducing adverse side effects like weight gain.
Spiro-cycle compounds inhibit beta-secretase activity, reducing beta-amyloid deposits and slowing cognitive decline in Alzheimer's disease.
Engineered rAAV9 vector expresses hNAGLU enzyme to reduce lysosomal storage burden and improve neuropathology scores in MPS IIIB patients.
Chemically defined culture conditions drive stem cells to differentiate into retinal progenitor cells within four weeks.
Pyrazol compounds act as selective Cannabinoid Receptor 2 agonists to reduce inflammation and fibrosis without activating Cannabinoid Receptor 1.
N-(2-arylamino) aryl sulfonamides inhibit MEK activity to treat hyperproliferative diseases while sparing normal cell function.
C-15 methyl thiazolyl substitution on estrone cores improves metabolic stability and selectivity for 17β-HSD1 over other isoforms.
Segmented heterocyclic amide structures achieve selective ROCK inhibition, minimizing side effects from off-target kinase activity.
Microgel and ionic polymer maintain ciclesonide dispersion homogeneity in sterile aqueous suspension formulations.
Combining quaternary ammonium salt with tertiary amine derivatives creates a pharmaceutical preparation with broad antimicrobial spectrum.
Time-release particles manage opioid side effects by sustaining plasma levels and avoiding hypotension spikes.
Merges metformin and galantamine at subtherapeutic doses to extend lifespan while avoiding side effects from high-dose monotherapy.
Grp94-selective compounds inhibit cancer cell migration and induce mutant myocilin degradation, minimizing off-target effects from pan-Hsp90 inhibition.
Genetic profiling selects rostafuroxin for patients with specific polymorphisms, achieving 8 to 22.5 mmHg blood pressure reduction.